▲ +120.24% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for BioCardia in the last 3 months. The average price target is $9.25, with a high forecast of $11.50 and a low forecast of $7.00. The average price target represents a 120.24% upside from the last price of $4.20.
The current consensus among 2 polled investment analysts is to buy stock in BioCardia.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.